-
Larimar Therapeutics NASDAQ:LRMR Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Location: Three Bala Plaza East. Suite 506, Pennsylvania, 19004, US | Website: larimartx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
23.7M
Cash
203.7M
Avg Qtr Burn
-14.57M
Short % of Float
15.88%
Insider Ownership
1.45%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nomlabofusp (CTI-1601) Details Rare diseases, Rare genetic disease, Friedreich’s Ataxia | BLA Submission |